Femasys (FEMY) AI Stock Analysis

• Market Cap: $38.71M
• Dividend Yield: N/A
• Average Volume (3M): 1.25M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.84
• Revenue Growth: 63.53%
• EPS Growth: 12.49%
• Country: US
• Employees: 69
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.10
• Shares Outstanding: 59,501,854
• 10 Day Avg. Volume: 939,048
• 30 Day Avg. Volume: 1,254,195
• PEG Ratio: 0.13
• Price to Book (P/B): 10.63
• Price to Sales (P/S): 15.04
• P/FCF Ratio: -1.21
• Enterprise Value/Market Cap: 0.47
• Enterprise Value/Revenue: 8.88
• Enterprise Value/Gross Profit: 20.96
• Enterprise Value/Ebitda: -1.08
• 1Y Price Target: $4.75
• Price Target Upside: 550.68% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -0.33
• Revenue Forecast (FY): $7.55M

• Rating: 41 Neutral
• Price Target: $0.66 ▼(-9.73% Downside)

The score is held down primarily by weak financial performance (ongoing losses and negative cash flow). Technicals remain soft-to-neutral with a negative MACD and price below key longer-term averages. Corporate events are mixed—FDA and commercialization progress are positives, but listing-compliance risk offsets much of that support.

Positive Factors

Regulatory Clearance

The 510(k) clearance for FemVue Controlled establishes a regulatory pathway for an integrated diagnostic platform that supports tubal patency assessment and streamlines clinical workflow. This durable approval lowers commercial barriers, aids clinician adoption, and supports broader product portfolio scaling in women’s health.

Clinical Milestone

Advancing FemBloc to the final FDA trial phase is a structural development that materially increases the probability of future U.S. market access for a non‑surgical permanent contraceptive. Successful completion could create a new, defensible product category and diversify long‑term revenue beyond diagnostics.

Early Commercial Traction

A substantial initial order in key European markets via distribution partnership demonstrates repeatable commercial demand and distribution execution. Early revenue and partner validation are durable indicators that the FemBloc value proposition can translate into scalable, recurring product and consumable sales overseas.

Negative Factors

Negative Cash Flow

Persistent negative operating and free cash flows, plus a negative free cash flow growth rate, constrain the company’s ability to fund trials and commercialization internally. Over a multi‑month horizon this raises dependency on external financing and limits investment in sales, manufacturing, and R&D execution.

Weak Profitability

Sustained negative net and EBIT margins alongside a shrinking gross profit margin signal structural challenges in converting revenue to profit. Without margin improvement or favorable product mix, the company may struggle to achieve durable profitability as revenues scale, pressuring long‑term sustainability.

Financing & Listing Risk

Ongoing reliance on equity and debt capital (ATM offering, filed share sales, $12M private placement with convertible notes) together with Nasdaq compliance deadlines indicate material financing risk. This structural dependence increases dilution and governance concessions, and poses execution risk if capital access tightens.

Femasys Business Overview & Revenue Model

Company Description

Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.

How the Company Makes Money

Femasys generates revenue primarily through the sale of its medical devices and systems designed for women's reproductive health. The company's revenue model is based on direct sales to healthcare providers, hospitals, and clinics that utilize its innovative technologies. Additionally, Femasys may engage in partnerships with other healthcare organizations and distributors to expand its market reach and enhance product visibility. Key revenue streams include product sales from its core offerings and potential licensing agreements or collaborations with larger medical companies that can leverage Femasys's technology in broader applications. The company may also benefit from grants or funding aimed at supporting women's health initiatives, further contributing to its financial performance.

Femasys Financial Statement Overview

Summary

Femasys shows revenue growth but struggles with profitability and cash flow. Negative net profit margins, EBIT margins, and cash flow deficits are concerning. Improved leverage management is a positive, but overall financial health is weak.

Income Statement

Femasys shows a positive revenue growth rate of 9.25% TTM, indicating some potential for growth. However, the company is struggling with profitability, as evidenced by negative net profit margins and EBIT margins. The gross profit margin has decreased significantly from previous years, which is concerning for long-term sustainability.

Balance Sheet

The debt-to-equity ratio has improved to 1.79 TTM from a high of 3.23, suggesting better leverage management. However, the return on equity remains negative, indicating inefficiencies in generating returns from equity. The equity ratio has decreased, reflecting a higher reliance on debt financing.

Cash Flow

Femasys's cash flow situation is challenging, with negative operating and free cash flows. The free cash flow to net income ratio is slightly above 1, indicating that cash flow is somewhat aligned with net income, but both are negative. The free cash flow growth rate is negative, highlighting ongoing cash flow issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.06M	1.63M	1.07M	1.21M	1.18M	1.04M
Gross Profit	873.85K	1.08M	691.90K	764.28K	809.30K	731.38K
EBITDA	-17.01M	-16.33M	-13.17M	-10.49M	-6.55M	-5.80M
Net Income	-19.80M	-18.82M	-14.25M	-11.39M	-7.54M	-6.91M
Balance Sheet
Total Assets	16.29M	12.45M	27.76M	16.90M	28.58M	7.61M
Cash, Cash Equivalents and Short-Term Investments	4.57M	3.45M	21.72M	12.96M	24.78M	3.32M
Total Debt	8.43M	7.44M	6.70M	543.72K	990.21K	2.06M
Total Liabilities	11.73M	10.14M	9.40M	1.65M	2.24M	4.08M
Stockholders Equity	4.56M	2.30M	18.35M	15.24M	26.33M	3.53M
Cash Flow
Free Cash Flow	-20.08M	-20.21M	-11.42M	-11.14M	-8.24M	-4.96M
Operating Cash Flow	-19.58M	-19.44M	-11.28M	-10.73M	-7.93M	-4.93M
Investing Cash Flow	-544.00K	-847.76K	-143.92K	-407.48K	-306.87K	968.32K
Financing Cash Flow	17.08M	2.03M	20.18M	-681.64K	29.70M	871.65K

Femasys Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.73
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FEMY, the sentiment is Neutral. The current price of 0.73 is above the 20-day moving average (MA) of 0.66, below the 50-day MA of 0.79, and below the 200-day MA of 0.80, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 46.21 is Neutral, neither overbought nor oversold. The STOCH value of 70.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FEMY.

Femasys Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
POCI	52 Neutral	$33.94M	-5.17	-57.98%	―	13.67%	-37.01%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NXGL	51 Neutral	$17.27M	-4.26	-58.34%	―	73.38%	34.87%
RVP	48 Neutral	$21.73M	-3.26	-8.05%	―	-0.95%	58.17%
MLSS	42 Neutral	$22.54M	-3.46	-136.47%	―	0.59%	-39.76%
FEMY	41 Neutral	$38.71M	-0.90	-376.23%	―	63.53%	12.49%

Femasys Corporate Events

Femasys Receives Nasdaq Extension to Regain Listing Compliance

On July 16, 2025, Femasys Inc. was notified by Nasdaq that its common stock had failed to meet the $1.00 per share minimum bid price requirement for 30 consecutive business days, triggering a potential delisting process. The company initially had until January 12, 2026, to regain compliance, and on that date it requested a 180-day extension, citing stockholders’ equity of more than $5 million as of December 31, 2025, and its intention to cure the deficiency, if needed, through a reverse stock split. On January 13, 2026, Nasdaq granted Femasys an extension until July 13, 2026, to restore its share price to at least $1.00 for ten consecutive business days, and the company plans to closely monitor its stock and consider options such as a reverse split to maintain its Nasdaq listing, a step that could affect shareholders and its market standing.

The most recent analyst rating on (FEMY) stock is a Sell with a $0.54 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.

Femasys Launches At-the-Market Common Stock Offering

On December 23, 2025, Femasys Inc. filed a prospectus supplement to offer and sell up to $9.8 million of its common stock under an existing Equity Distribution Agreement with Piper Sandler & Co., using an at-the-market offering program under a previously effective shelf registration. The arrangement allows Femasys, at its discretion, to direct Piper Sandler to sell shares from time to time subject to customary parameters, enhancing the company’s financial flexibility and providing an additional mechanism to raise capital as needed while operating within established securities law frameworks.

The most recent analyst rating on (FEMY) stock is a Hold with a $0.79 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.

Femasys Gains FDA Clearance for FemVue Diagnostic Device

On December 18, 2025, Femasys Inc. reported that it had received 510(k) clearance from the U.S. Food and Drug Administration for its FemVue Controlled diagnostic device, a next-generation solution for controlled contrast delivery during ultrasound imaging to evaluate fallopian tube status. The device combines features of the company’s original FemVue and FemChec technologies into a single FDA-cleared platform, supporting multiple clinical uses such as confirming tubal patency before FemaSeed procedures and is intended to simplify care delivery, enhance workflow efficiency in clinical practice, and streamline manufacturing as Femasys expands its integrated fertility and women’s health product portfolio.

The most recent analyst rating on (FEMY) stock is a Hold with a $0.82 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.

Femasys Secures Major Order for FemBloc Launch

On November 6, 2025, Femasys Inc. announced a significant initial order valued at approximately $500,000 USD for the commercial launch of FemBloc Permanent Birth Control in France and the Benelux region through its partnership with Kebomed. This order marks continued progress in expanding FemBloc’s presence across key European markets, reflecting growing international momentum for this innovative, non-surgical permanent contraceptive solution. FemBloc, a first-of-its-kind non-surgical solution for permanent birth control, addresses a significant unmet need in women’s reproductive health by providing a safer, more convenient, and affordable option compared to surgical sterilization.

The most recent analyst rating on (FEMY) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.

Femasys Secures $12 Million Through Private Placement

Femasys Inc. announced on November 3, 2025, that it has entered into a Securities Purchase Agreement with accredited investors to raise $12 million through a private placement of senior secured convertible notes and warrants. The proceeds will be used to repay existing debt and for general corporate purposes, with company insiders participating in the investment. The agreement grants the lead lender a board nomination right and includes customary covenants and restrictions.

The most recent analyst rating on (FEMY) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.

Femasys Receives FDA Approval for FemBloc Trial

On November 3, 2025, Femasys Inc. announced it has received FDA approval to advance the final phase of the FemBloc trial, a non-surgical permanent birth control method, marking a significant step towards potential U.S. market entry. Additionally, Femasys secured $12 million in financing, with potential to reach $58 million, which will be used to refinance existing debt and support the commercialization of its fertility and birth control portfolio, reflecting strong investor confidence in the company’s mission to transform women’s health.

The most recent analyst rating on (FEMY) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.

Femasys Meets Nasdaq Equity Requirement After Offering

On May 19, 2025, Femasys Inc. received a notice from Nasdaq indicating that its common stock had fallen below the minimum market value requirement for continued listing. However, after a recent offering and warrant exercises, the company reported a pro forma stockholders’ equity of approximately $5.2 million as of October 15, 2025, meeting Nasdaq’s minimum requirement. Nasdaq will continue to monitor Femasys’ compliance, and failure to maintain these standards could result in delisting.

The most recent analyst rating on (FEMY) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.

Femasys COO Daniel Currie Announces Retirement

On October 13, 2025, Daniel Currie, Chief Operating Officer of Femasys Inc., announced his retirement effective December 15, 2025, after over 20 years with the company. His departure is due to personal health reasons and a desire to focus on family. The company has entered into a Separation Agreement with Currie, ensuring the vesting of unvested stock options and continuation of health benefits through 2026. The Board of Directors expressed their gratitude for his leadership and service.

The most recent analyst rating on (FEMY) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.